Phase 2 Primary Biliary Cholangitis Trial, Not Yet Recruiting NCT07477782 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Primary Biliary Cholangitis
Back to Primary Biliary Cholangitis

Phase 2 Primary Biliary Cholangitis Trial, Not Yet Recruiting

NCT07477782
Not Yet Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a man or woman aged between 18 and 75 years old
  • You have been diagnosed with a type of primary sclerosing cholangitis (PSC) affecting the larger bile ducts, confirmed by a specific imaging scan or procedure of the bile ducts
  • You have been diagnosed with inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis, confirmed by camera examination and tissue samples
  • Your IBD has been stable (not flaring up) for at least the last 6 months, with no changes to your IBD treatment during that time
  • Your liver blood test results show certain elevated levels (a specific liver enzyme or bilirubin) on at least 2 tests in the 3 months before joining
  • You have been taking a medication called UDCA at a specific dose for at least 6 months, with the same dose for at least the last 3 months
  • If you are a woman who could become pregnant, you agree to use a highly effective form of contraception from the start of the trial until week 48
  • You are able and willing to give written consent to take part
  • You are registered with the French Social Security system

Who may not be able to join:

  • You have the smaller duct form of PSC (called small duct PSC)
  • You have been diagnosed with autoimmune hepatitis (a separate liver condition), confirmed by liver biopsy and certain blood test results
  • You have a different cause of bile duct scarring, such as IgG4-related disease
  • You have cirrhosis (severe liver scarring), shown by a liver stiffness scan result above a certain level, or you have had complications from cirrhosis in the past or currently
  • Your liver enzyme levels (AST or ALT) have been more than 7 times the normal upper limit in the last 3 months
  • Your platelet count (cells that help blood clot) was below a certain level in the last 3 months
  • Your albumin (a protein in your blood) was below a certain level in the last 3 months
  • Your blood clotting ability (prothrombin index) was below a certain level in the last 3 months
  • You have another liver condition such as hepatitis B or C, heavy alcohol use, a fatty liver disease, primary biliary cholangitis, haemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency, or coeliac disease
  • You have had an acute bile duct infection (acute cholangitis) in the last 3 months, or you currently have one
  • You have HIV infection
  • You have previously had a liver transplant
  • You have had or are planned to have a procedure to treat a blocked bile duct within 3 months before or after joining the trial
  • You have a history of, or suspected, cancer of the liver or bile ducts
  • You have a serious illness that may significantly shorten your life expectancy
  • You have been diagnosed with or treated for any cancer in the last 2 years (some minor skin cancers or treated cervical conditions may be acceptable — confirm with trial site)
  • Your liver disease treatment has changed or a new liver treatment was started in the last 3 months
  • You have a history of bowel cancer or high-grade abnormal cells found during a previous bowel camera examination
  • You have had your entire large bowel (colon) surgically removed
  • Your IBD is currently active, based on specific scoring measures used by doctors
  • Your IBD treatment has changed or a new IBD treatment was started in the last 3 months
  • You are currently taking certain IBD medicines including biologics (such as anti-TNF drugs, vedolizumab, or ustekinumab), certain anti-inflammatory tablets (JAK inhibitors), or steroid doses above a certain level
  • You are unable to swallow capsules
  • Your kidneys are not working well enough (below a certain filtration level)
  • You are unable to give consent freely, or you are under a legal protection order, detained, or receiving involuntary psychiatric care
  • You are currently taking part in another clinical intervention trial (confirm with trial site if unsure)
  • You are pregnant, trying to become pregnant, or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sara LEMOINNE, MD, PhD, PU-PH, APHP

Phone: +33 1 49 28 28 36

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
1 April 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

To assess in patients with PSC the efficacy of FMT versus sham transplantation on ALP and bilirubin at week 48 addition to standard UDCA therapy.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov